Cosunter(SZ:300436) Xin Lang Cai Jing·2026-01-05 02:33Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.04% to 93.64 CNY per share, with a trading volume of 259 million CNY and a turnover rate of 2.07%, resulting in a total market capitalization of 14.914 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund is among the top shareholders of Guangshentang. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 16.977 billion CNY. The fund has achieved a return of 13.07% this year, ranking 5369 out of 8155 in its category [2] - The fund manager, Ge Lan, has a tenure of 10 years and 345 days, with the fund's total asset scale at 43.544 billion CNY and a best return of 95.14% during the tenure [3]